150 related articles for article (PubMed ID: 1302039)
1. Clinical implications of variable antiarrhythmic drug metabolism.
Buchert E; Woosley RL
Pharmacogenetics; 1992 Feb; 2(1):2-11. PubMed ID: 1302039
[TBL] [Abstract][Full Text] [Related]
2. In vitro assessment of various cytochromes P450 and glucuronosyltransferases using the antiarrhythmic propafenone as a probe drug.
Kroemer HK; Botsch S; Heinkele G; Schick M
Methods Enzymol; 1996; 272():99-105. PubMed ID: 8791766
[No Abstract] [Full Text] [Related]
3. Clinical pharmacology of antiarrhythmic drugs: variability of metabolism and dose requirements.
Follath F
J Cardiovasc Pharmacol; 1991; 17 Suppl 6():S74-6. PubMed ID: 1723123
[TBL] [Abstract][Full Text] [Related]
4. Clinical pharmacokinetics of the newer antiarrhythmic agents.
Gillis AM; Kates RE
Clin Pharmacokinet; 1984; 9(5):375-403. PubMed ID: 6437721
[TBL] [Abstract][Full Text] [Related]
5. Stereoselective genetically-determined interaction between chronic flecainide and quinidine in patients with arrhythmias.
Birgersdotter UM; Wong W; Turgeon J; Roden DM
Br J Clin Pharmacol; 1992 Mar; 33(3):275-80. PubMed ID: 1576047
[TBL] [Abstract][Full Text] [Related]
6. Antiarrhythmic agents: drug interactions of clinical significance.
Trujillo TC; Nolan PE
Drug Saf; 2000 Dec; 23(6):509-32. PubMed ID: 11144659
[TBL] [Abstract][Full Text] [Related]
7. New drugs in the management of ventricular arrhythmias.
Sanna GP
G Ital Cardiol; 1984 Oct; 14(10):788-97. PubMed ID: 6083894
[TBL] [Abstract][Full Text] [Related]
8. Aggravation of ventricular arrhythmia. A drug-induced complication.
Podrid PJ
Drugs; 1985; 29 Suppl 4():33-44. PubMed ID: 3924550
[TBL] [Abstract][Full Text] [Related]
9. Clinical significance of genetic influences on cardiovascular drug metabolism.
Arcavi L; Benowitz NL
Cardiovasc Drugs Ther; 1993 Jun; 7(3):311-24. PubMed ID: 8103355
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetic and pharmacodynamic interaction between mexiletine and propafenone in human beings.
Labbé L; O'Hara G; Lefebvre M; Lessard E; Gilbert M; Adedoyin A; Champagne J; Hamelin B; Turgeon J
Clin Pharmacol Ther; 2000 Jul; 68(1):44-57. PubMed ID: 10945315
[TBL] [Abstract][Full Text] [Related]
11. New antiarrhythmic drugs.
Nestico PF; Morganroth J; Horowitz LN
Drugs; 1988 Mar; 35(3):286-319. PubMed ID: 3286214
[TBL] [Abstract][Full Text] [Related]
12. Role of polymorphic debrisoquin 4-hydroxylase activity in the stereoselective disposition of mexiletine in humans.
Abolfathi Z; Fiset C; Gilbert M; Moerike K; Bélanger PM; Turgeon J
J Pharmacol Exp Ther; 1993 Sep; 266(3):1196-201. PubMed ID: 8371133
[TBL] [Abstract][Full Text] [Related]
13. Overview of the clinical pharmacology of antiarrhythmic drugs.
Woosley RL; Funck-Brentano C
Am J Cardiol; 1988 Jan; 61(2):61A-69A. PubMed ID: 2447771
[TBL] [Abstract][Full Text] [Related]
14. Investigational antiarrhythmic drugs for the treatment of ventricular rhythm disturbances.
Pratt CM; Luck JC; Mann DE; Wyndham CR
Cardiol Clin; 1984 Feb; 2(1):35-46. PubMed ID: 6443563
[TBL] [Abstract][Full Text] [Related]
15. Polymorphism of dextromethorphan metabolism: relationships between phenotype, genotype and response to the administration of encainide in humans.
Funck-Brentano C; Thomas G; Jacqz-Aigrain E; Poirier JM; Simon T; Béréziat G; Jaillon P
J Pharmacol Exp Ther; 1992 Nov; 263(2):780-6. PubMed ID: 1432700
[TBL] [Abstract][Full Text] [Related]
16. Clinical profiles of newer class I antiarrhythmic agents--tocainide, mexiletine, encainide, flecainide and lorcainide.
Pottage A
Am J Cardiol; 1983 Sep; 52(6):24C-31C. PubMed ID: 6414279
[TBL] [Abstract][Full Text] [Related]
17. Impact of stereoselectivity on the pharmacokinetics and pharmacodynamics of antiarrhythmic drugs.
Mehvar R; Brocks DR; Vakily M
Clin Pharmacokinet; 2002; 41(8):533-58. PubMed ID: 12102640
[TBL] [Abstract][Full Text] [Related]
18. Antiarrhythmic drug therapy (Part 2). Benefits and hazards.
Podrid PJ
Chest; 1985 Oct; 88(4):618-24. PubMed ID: 3930162
[No Abstract] [Full Text] [Related]
19. Importance of metabolites in antiarrhythmic therapy.
Woosley RL; Roden DM
Am J Cardiol; 1983 Sep; 52(6):3C-7C. PubMed ID: 6194679
[TBL] [Abstract][Full Text] [Related]
20. The clinical use of class IC antiarrhythmic drugs.
Abi Samra F
J La State Med Soc; 1989 May; 141(5):27-31. PubMed ID: 2499646
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
